Trial Profile
A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Imifoplatin (Primary)
- Indications Advanced breast cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms PAVE; PAVE-1
- Sponsors Promontory Therapeutics
- 31 May 2023 Status changed from active, no longer recruiting to completed as per Promontory Therapeutics Media Release.
- 08 Dec 2022 Phase 2a results published in the Promontory Therapeutics Media Release.
- 08 Dec 2022 According to Promontory Therapeutics media release, data from the study was presented at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2022.